Skip to content
ClinCalc Pro
Menu
Opioid Analgesic (Moderate-Strong)

Oxycodone

Brand names: OxyNorm, OxyContin (modified release)

Oxycodone is a strong opioid analgesic used for moderate-to-severe acute post-operative pain, available in oral and parenteral forms within a multimodal regimen.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Oxycodone is a potent agonist principally at mu-opioid receptors, inhibiting ascending pain pathways and modifying the perception of pain.

Prescribing in practice

  • As with all strong opioids the key hazard is dose-related respiratory depression and sedation — titrate to effect, avoid concurrent sedatives where possible, and ensure naloxone and monitoring are available.
  • Oxycodone is metabolised hepatically and partly renally excreted, so reduce dosing and extend intervals in hepatic or renal impairment and in the elderly.
  • Anticipate and manage opioid constipation, nausea and the risk of dependence; switch to non-opioid analgesia as pain improves.

Monitoring

Monitor pain score, sedation level, respiratory rate and bowel function, with closer observation after dose changes or in organ impairment.

Counselling the patient

  • This is a strong painkiller for after your operation — take it as prescribed and step down as pain eases.
  • It can cause drowsiness and constipation; do not drive while affected.
  • Report excessive sleepiness or slow breathing immediately.

Evidence & guidelines

Oxycodone is an established strong opioid for acute post-operative pain within multimodal analgesia.

Reference: OxyNorm SPC; FACULTY of Pain Medicine Opioid Prescribing Guidelines; PROSPECT Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.